Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

January 06, 2009; 72 (1) Correspondence

MULTIPLE SCLEROSIS AND CANNABIS: A COGNITIVE AND PSYCHIATRIC STUDY

Lambros Messinis, Panagiotis Papathanasopoulos
First published January 2, 2009, DOI: https://doi.org/10.1212/01.wnl.0000339406.02332.79
Lambros Messinis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panagiotis Papathanasopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
MULTIPLE SCLEROSIS AND CANNABIS: A COGNITIVE AND PSYCHIATRIC STUDY
Lambros Messinis, Panagiotis Papathanasopoulos
Neurology Jan 2009, 72 (1) 100-101; DOI: 10.1212/01.wnl.0000339406.02332.79

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
200

Share

  • Article
  • Info & Disclosures
Loading

To the Editor:

Drs. Ghaffar and Feinstein1 report important new data associating regular smoking of street cannabis in patients with multiple sclerosis (MS) with more extensive cognitive abnormalities compared to patients with MS who do not use cannabis.

In 2006 we reported subtle deficits in specific neuropsychological domains in heavy, long-term cannabis users that were in the unintoxicated state.2 The Ghaffar and Feinstein report provides evidence that patients with MS might suffer additional cognitive decline when smoking cannabis regularly.1

However, cognitive deficits that have been attributed to regular recreational use of cannabis are not necessarily extended to controlled pharmaceutical use of cannabis-based medicinal extracts (CBMEs). However, the findings of Ghaffar and Feinsten form the basis on which to raise concern regarding potential cognitive adverse effects of long-term regular cannabis use in MS.

We recently reviewed MS clinical trial data of CBMEs and specifically focused on parallel assessments of cognitive status in order to establish whether any disruptive effects on cognition had been documented in these trials.3 Available data indicated that no significant cognitive decline occurs after relatively short-term administration of CBMEs. However, safer and more valid conclusions will have to await the results of long-term, large-scale, systematic clinical trials of CBMEs.

In addition, the Ghaffar and Feinstein report did not adjust for premorbid cognitive ability between groups of patients with MS.1 By matching groups on measures of crystallized intelligence that are relatively resilient to brain impairment (i.e., Wechsler Abbreviated Scale of Intelligence [Vocabulary scale] or National Adult Reading Test), groups may be more equal with regard to premorbid cognitive abilities. MS cannabis users reporting greater cognitive deficits may reflect premorbid cognitive impairments rather than consequences of cannabis exposure.

Another important limitation of this study1 concerns the potential neurocognitive effects of cannabis withdrawal syndrome. This may have influenced the results as MS cannabis users were noted to have used cannabis 1–30 days before testing.4

Because the study does not provide mean duration of abstinence from cannabis use by patients with MS, we might assume that the findings regarding the more extensive cognitive abnormalities actually reflect acute effects of cannabis on cognition and cannot be certain that these differences would persist after adequate abstinence periods.

Despite the important contribution of this new study, the findings should be interpreted within the context of these important caveats.

Disclosure: The authors report no disclosures.

Reply from the Authors:

Drs. Messinis and Papathanasopoulos raise interesting and pertinent questions related to our findings that inhaled cannabis is associated with greater impairment in speed of information processing in patients with MS.1

We agree that this finding may not apply to CBMEs and acknowledged this in our article’s concluding sentence. However, it is still unclear whether the long-term use of pharmaceutically derived CBMEs affects cognitive function, a point made by Drs. Messinis and Papathanasopoulos in their recent comprehensive review.3

Other factors could have influenced cognitive functioning in our sample apart from the use of inhaled cannabis. We did not use the ANART or the vocabulary subscale of the Wechsler Abbreviated Scale of Intelligence to control for premorbid intelligence, but rather relied on the number of years of completed education, which did not differ between our cannabis users and control subjects.

We subsequently ran a second analysis which reviewed the possible differences in occupational category (professional and skilled versus other) and again did not find between-group differences (χ2 = 0.2; p = 0.0.72; Fisher exact test). While these data are not as robust as those obtained from psychometric measures, they indicate that inhaled cannabis rather than premorbid intellect explains the cognitive findings.

The question of whether the greater cognitive deficits recorded in our cannabis users were influenced by a cannabis withdrawal syndrome is intriguing. In general, while the data supporting the validity of this syndrome appear compelling, it is less clear whether altered cognition is part of the clinical picture.

Only one out of 10 studies investigating the clinical picture of cannabis abstinence listed impaired concentration as the sole cognitive complaint,4 leading Budney et al.5 to omit any reference to impaired cognition as part of their suggested criteria for the syndrome.

Based on the existing literature, it seems unlikely that the cognitive problems identified in our cannabis smokers are a function of a withdrawal syndrome, but we cannot be certain of this given the limitations in our data. We did not collect information on precisely how much time had elapsed between our subjects smoking cannabis and their completing the neuropsychological battery. As with so much in the field, further research is needed to explore these issues.

Disclosure on article to which this Correspondence refers: O.G. has received honoraria from Cerebrio, a continuing medical education company. A.F. has received lecture honoraria from Berlex Canada, Serono Canada, Serono USA, Teva Neuroscience, and Avanir Pharmaceuticals.

1 Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008;71:164–169.OpenUrlAbstract/FREE Full Text

2 Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P. Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006;66:737–739.OpenUrlAbstract/FREE Full Text

3 Papathanasopoulos P, Messinis L, Lyros E, Kastellakis A, Panagis G. Multiple sclerosis, cannabinoids and cognition. J Neuropsychiatry Clin Neurosci 2008;20: 36–51.

4 Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161:1967–1977.OpenUrlCrossRefPubMed

5 Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006;19:233–238.OpenUrlCrossRefPubMed

View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • To the Editor:
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise